In another study, in patients with advanced NSCLC and PD-L1 expression, pembrolizumab was associated with significantly longer progression-free and overall survival and with fewer adverse events in comparison to platinum-based chemotherapy [28]. Here, CD274 is linked to non-small cell lung carcinoma.